Evidence map›Paper›PMID 25455989›Full record

Observational studyThe Lancet. Infectious diseases2014

Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study.

Nikolay P Braykov, Daniel J Morgan, Marin L Schweizer, Daniel Z Uslan, Theodoros Kelesidis, Scott A Weisenberg, Birgir Johannsson, Heather Young, Joseph Cantey, Arjun Srinivasan and 3 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in The Lancet. Infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Sepsis in the absence of fever: Determining the criteria for and feasibility of future therapeutic temperature management trials.Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Ultra-Short-Course Antibiotics for Suspected Pneumonia With Preserved Oxygenation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Simplified therapeutic guidelines: the main tool of antimicrobial stewardship programs associated with optimal antibiotic therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Article
  20. Antibiotic Use and Presumptive Pathogens in the Veterans Affairs Healthcare System.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 2 countries.

Nikolay P BraykovCenter for Disease Dynamics, Economics and Policy, Washington, DC, USA.
Daniel J MorganDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Marin L SchweizerDepartment of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, IA, USA.
Daniel Z UslanInfectious Diseases, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Theodoros KelesidisInfectious Diseases, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Scott A WeisenbergAlta Bates Summit Medical Center, Oakland, CA, USA.
Birgir JohannssonDepartment of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Heather YoungInfectious Diseases, Denver Health Medical Center, Denver, CO, USA.
Joseph CanteyPediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Arjun SrinivasanCenters for Disease Control and Prevention, Atlanta, GA, USA.
Eli PerencevichDepartment of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA; Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City VA Health Care System, Iowa City, IA, USA.
Edward SeptimusClinical Services Group, HCA Inc, Nashville, TN, USA; Texas A&M Health Science Center College of Medicine, Houston, TX, USA.
Ramanan LaxminarayanCenter for Disease Dynamics, Economics and Policy, Washington, DC, USA; Public Health Foundation of India, New Delhi, India; Princeton University, Princeton, NJ, USA. Electronic address: ramanan@cddep.org.
University of California, Los Angeles · USUniversity of Iowa · USAlta Bates Summit Medical Center · USCenter for Disease Dynamics, Economics & Policy · USCenters for Disease Control and Prevention · USDenver Health Medical Center · USHCA Healthcare · USIowa City VA Health Care System · USPublic Health Foundation of India · INThe University of Texas Southwestern Medical Center · USUniversity of Maryland, Baltimore · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
University of Iowa Clinical and Translational Science ProgramUL1TR000442 · NCATS · UNIVERSITY OF IOWA · PI ROSENTHAL, GARY E · 2012 to 2013
$10.0M
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosisK08AI108272 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2013 to 2017
$915k
NCATS NIH HHS 2 UL1 TR000442-06NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR000442NCATS NIH HHS UL1 TR001881NIAID NIH HHS K08 AI108272
6 · The paper itself

Abstract

backgroundModification of empirical antimicrobials when warranted by culture results or clinical signs is recommended to control antimicrobial overuse and resistance. We aimed to assess the frequency with which patients were started on empirical antimicrobials, characteristics of the empirical regimen and the clinical characteristics of patients at the time of starting antimicrobials, patterns of changes to empirical therapy at different timepoints, and modifiable factors associated with changes to the initial empirical regimen in the first 5 days of therapy.

methodsWe did a chart review of adult inpatients receiving one or more antimicrobials in six US hospitals on 4 days during 2009 and 2010. Our primary outcome was the modification of antimicrobial regimen on or before the 5th day of empirical therapy, analysed as a three-category variable. Bivariate analyses were used to establish demographic and clinical variables associated with the outcome. Variables with p values below 0·1 were included in a multivariable generalised linear latent and mixed model with multinomial logit link to adjust for clustering within hospitals and accommodate a non-binary outcome variable.

findingsAcross the six study sites, 4119 (60%) of 6812 inpatients received antimicrobials. Of 1200 randomly selected patients with active antimicrobials, 730 (61%) met inclusion criteria. At the start of therapy, 220 (30%) patients were afebrile and had normal white blood cell counts. Appropriate cultures were collected from 432 (59%) patients, and 250 (58%) were negative. By the 5th day of therapy, 12·5% of empirical antimicrobials were escalated, 21·5% were narrowed or discontinued, and 66·4% were unchanged. Narrowing or discontinuation was more likely when cultures were collected at the start of therapy (adjusted OR 1·68, 95% CI 1·05-2·70) and no infection was noted on an initial radiological study (1·76, 1·11-2·79). Escalation was associated with multiple infection sites (2·54, 1·34-4·83) and a positive culture (1·99, 1·20-3·29).

interpretationBroad-spectrum empirical therapy is common, even when clinical signs of infection are absent. Fewer than one in three inpatients have their regimens narrowed within 5 days of starting empirical antimicrobials. Improved diagnostic methods and continued education are needed to guide discontinuation of antimicrobials.

fundingUS Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion; Robert Wood Johnson Foundation; US Department of Veterans Administration; US Department of Homeland Security.

Indexed as

AdultAgedAged, 80 and overAnti-Bacterial AgentsBacterial InfectionsCohort StudiesFemaleHospitalsHumansMaleMiddle AgedTreatment OutcomeUnited StatesYoung AdultAnti-Bacterial Agents

Identifiers

PMID25455989
PMCPMC5525058
OpenAlexW2148185413

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.